Takeda Looks To Double Emerging Market Revenues
Focus Will Be On Innovation
Japanese firm aims for growth ahead of the market as it rolls out global innovative products and its Wave 1 portfolio across emerging markets, aided by "targeted investments".
You may also be interested in...
Maverick’s bispecific antibody program adds to Takeda’s expanding immuno-oncology development business, which also includes cell therapy programs.
Takeda tries to get investors as excited as it is about the first wave of post-R&D reorganization candidates coming through, as it lays out 'ambitious but achievable' revenue target.
Chinese venture Brii seeks US emergency authorization for its antibody combo, as Chugai aims for wider use of its antibody cocktail in Japan and two other Chinese firms link up on an oral antiviral.